Mipletamig is under clinical development by Aptevo Therapeutics and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase II drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Mipletamig’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mipletamig overview
APVO-436 is under development for the treatment of relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome. It is a bi-specific antibody. It acts by targeting CD123 and CD3. The drug candidate is administered through intravenous route. It is developed based on the ADAPTIR and OmniAb platform technology. It was also under development for the treatment of acute lymphocytic leukemia and hairy cell leukemia.
Aptevo Therapeutics overview
Aptevo Therapeutics (Aptevo) is a clinical-stage biotechnology company. It is developing innovative immunotherapy candidates for cancer treatment using its Adaptir and Adaptir-Flex platforms that enable the creation of monospecific, bispecific, and multi-specific immunotherapeutic proteins to enhance or regulate immune responses. Aptevo’s research and development pipeline includes Mipletamig for treating acute myeloid leukemia (AML) and ALG.APV-527, which targets 4-1BB and the 5T4 antigen in various solid tumors. The company is also advancing several preclinical candidates, including APVO603, a dual agonist that targets both 4-1BB and OX40; APVO442, which is designed for prostate cancer; and APVO711, which stimulates CD40 while inhibiting the PD-1/PD-L1 pathway. Aptevo is headquartered in Seattle, Washington, the US.
For a complete picture of Mipletamig’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
